supply of ghm/2/2026-27 injection part 2/3 - japanese encephalitis vaccine, meningococcal vaccine, inj. human papillomavirus (hpv) vaccine (bivalent), inj. human papillomavirus (hpv) vaccine (quadrivalent), inj. human papillomavirus (hpv) vaccine (9-valent), inj. pneumococcal conjugate vaccine (pcv13), inj. pneumococcal conjugate vaccine (pcv15), inj. pneumococcal conjugate vaccine (pcv20), inj. pneumococcal polysaccharide vaccine (ppsv23), inj. haemophilus influenzae type b (hib) vaccine, inj.

Health And Family Welfare Department has invited bids for the supply of ghm/2/2026-27 injection part 2/3 - japanese encephalitis vaccine, meningococcal vaccine, inj. human papillomavirus (hpv) vaccine (bivalent), inj. human papillomavirus (hpv) vaccine (quadrivalent), inj. human papillomavirus (hpv) vaccine (9-valent), inj. pneumococcal conjugate vaccine (pcv13), inj. pneumococcal conjugate vaccine (pcv15), inj. pneumococcal conjugate vaccine (pcv20), inj. pneumococcal polysaccharide vaccine (ppsv23), inj. haemophilus influenzae type b (hib) vaccine, inj. pentavalent vaccine (dpt + hepatitis b + hib), inj. hexavalent vaccine (dtap + ipv + hib + hepatitis b), inj. rotavirus vaccine, inj. measles, mumps & rubella (mmr) vaccine, inj. measles, mumps, rubella & varicella (mmrv) vaccine, inj. varicella (chickenpox) vaccine, inj. herpes zoster (shingles) vaccine (recombinant), inj. dengue vaccine, inj. respiratory syncytial virus (rsv) vaccine, inj. meningococcal acwy vaccine, inj. meningococcal b vaccine, inj. cholera vaccine (injectable, where available), inj. typhoid conjugate vaccine (tcv), inj. hepatitis a vaccine, inj. recombinant zoster vaccine, inj. covid-19 mrna vaccine, inj. covid-19 protein subunit vaccine, inj. japanese encephalitis vaccine, inj. yellow fever vaccine, inj. tick-borne encephalitis vaccine, inj. human insulin regular 40 iu/ml, inj. human insulin regular 100 iu/ml, inj. human insulin nph 40 iu/ml, inj. human insulin nph 100 iu/ml, inj. human insulin 70/30 premix 40 iu/ml, inj. human insulin 70/30 premix 100 iu/ml, inj. insulin aspart 100 iu/ml, inj. insulin lispro 100 iu/ml, inj. insulin glargine 100 iu/ml, inj. insulin detemir 100 iu/ml, inj. insulin degludec 100 iu/ml, inj. biphasic insulin aspart 30/70, inj. biphasic insulin lispro 25/75, inj. leuprolide acetate 22.5 mg, inj. goserelin 3.6 mg implant, inj. goserelin 10.8 mg implant, inj. triptorelin pamoate 3.75 mg, inj. triptorelin pamoate 11.25 mg, inj. degarelix 80 mg, inj. degarelix 120 mg.. Please refer to the tender document for project value and EMD details. Interested bidders can submit applications until 23 September 2026, with the technical opening scheduled for 23 September 2026.